Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I.

Gynecol Oncol. 2019 Nov;155(2):262-269. doi: 10.1016/j.ygyno.2019.09.008. Epub 2019 Oct 8.

PMID:
31604666
2.

Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.

De La Motte Rouge T, Corné J, Cauchois A, Le Boulch M, Poupon C, Henno S, Rioux-Leclercq N, Le Pabic E, Laviolle B, Catros V, Levêque J, Fautrel A, Le Gallo M, Legembre P, Lavoué V.

Mol Cancer Res. 2019 Dec;17(12):2537-2548. doi: 10.1158/1541-7786.MCR-19-0449. Epub 2019 Sep 19.

PMID:
31537619
3.

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.

Pujol P, De La Motte Rouge T, Penault-Llorca F.

Diagnostics (Basel). 2019 Jul 26;9(3). pii: E83. doi: 10.3390/diagnostics9030083.

4.

Therapeutic innovations in breast cancer.

Le Du F, Perrin C, Brunot A, Crouzet L, De La Motte Rouge T, Lefeuvre-Plesse C, Dieras V.

Presse Med. 2019 Oct;48(10):1131-1137. doi: 10.1016/j.lpm.2019.04.005. Epub 2019 May 29.

PMID:
31151842
5.

Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology.

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.

J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):369-378. doi: 10.1016/j.jogoh.2019.03.017. Epub 2019 Mar 30.

6.

Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up).

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.

J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):379-386. doi: 10.1016/j.jogoh.2019.03.018. Epub 2019 Mar 29.

7.

Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa.

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.

Eur J Obstet Gynecol Reprod Biol. 2019 May;236:214-223. doi: 10.1016/j.ejogrb.2019.03.010. Epub 2019 Mar 15.

8.

[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.

Bull Cancer. 2019 Apr;106(4):354-370. doi: 10.1016/j.bulcan.2019.01.014. Epub 2019 Mar 6. Review. French.

PMID:
30850152
9.
10.

[Part II drafted from the short text of the French guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly, fertility preservation, follow-up)].

Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.

Gynecol Obstet Fertil Senol. 2019 Feb;47(2):111-119. doi: 10.1016/j.gofs.2018.12.011. Epub 2019 Jan 28. French.

PMID:
30704955
11.

[Part I drafted from the short text of the French Guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative care, and pathological analysis)].

Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E.

Gynecol Obstet Fertil Senol. 2019 Feb;47(2):100-110. doi: 10.1016/j.gofs.2018.12.010. Epub 2019 Jan 24. French.

PMID:
30686724
12.

Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.

Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Mazouni C, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, de La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Robain M, Filleron T, Cailliot C, Dalenc F.

Ann Surg Oncol. 2019 Feb;26(2):356-365. doi: 10.1245/s10434-018-6831-9. Epub 2018 Dec 11.

PMID:
30539492
13.

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).

Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W, Schnitzler A, Baulande S, Rivera S, Mouret-Reynier MA, Bouvet LV, De La Motte Rouge T, Lemonnier J, Lerebours F, Callens C.

J Hematol Oncol. 2018 Oct 11;11(1):124. doi: 10.1186/s13045-018-0670-9.

14.

Tumor analysis: freeze-thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells.

Le Gallo M, de la Motte Rouge T, Poissonnier A, Lavoué V, Tas P, Leveque J, Godey F, Legembre P.

BMC Res Notes. 2018 Jun 20;11(1):401. doi: 10.1186/s13104-018-3504-5.

15.

[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].

Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Joly Lobbedez F.

Bull Cancer. 2018 May;105(5):465-474. doi: 10.1016/j.bulcan.2018.01.015. Epub 2018 Mar 12. French.

PMID:
29544693
16.

Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey.

Viguier J, Morère JF, Pivot X, Touboul C, Lhomel C, Couraud S, de La Motte Rouge T, Eisinger F.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):14. doi: 10.1007/s11912-017-0646-x.

PMID:
29508088
17.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I.

Bull Cancer. 2018 Mar;105(3):299-314. doi: 10.1016/j.bulcan.2017.10.032. French.

PMID:
29397916
18.

Cancer de l’ovaire : la rechute précoce.

Pautier P, Kalbacher E, de la Motte Rouge T, Bonnetain F, Lesoin A.

Bull Cancer. 2017 May;104 Suppl 1:S32-S38. doi: 10.1016/S0007-4551(17)30160-1. French.

PMID:
28625313
19.

[Can new molecular profiles in epithelial ovarian cancer modify therapeutics?]

Lavoué V, Rousselin A, Delplanque S, Pinsard M, Henno S, Foucher F, Levêque J, de la Motte Rouge T.

J Gynecol Obstet Hum Reprod. 2017 Feb;46(2):107-112. doi: 10.1016/j.jogoh.2016.09.002. Epub 2017 Jan 30. Review. French.

20.

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

de la Motte Rouge T, Pautier P, Genestie C, Rey A, Gouy S, Leary A, Haie-Meder C, Kerbrat P, Culine S, Fizazi K, Lhommé C.

Gynecol Oncol. 2016 Sep;142(3):452-7. doi: 10.1016/j.ygyno.2016.07.005. Epub 2016 Jul 8.

PMID:
27401840
21.

Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.

Pelissier A, Bonneau C, Chéreau E, DE LA Motte Rouge T, Fourchotte V, Daraï E, Rouzier R.

Anticancer Res. 2016 Apr;36(4):1865-71.

PMID:
27069172
22.

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, Uro-Coste E, de Braud F, Pelosi G, French CA.

Cancer Discov. 2016 May;6(5):492-500. doi: 10.1158/2159-8290.CD-15-1335. Epub 2016 Mar 14.

23.

[Fertility sparing treatment in women affected by cervical cancer larger than 2cm].

Estevez JP, Hequet D, Dubot C, Fourchotte V, De La Motte Rouge T, Becette V, Rouzier R.

Bull Cancer. 2016 Feb;103(2):173-9. doi: 10.1016/j.bulcan.2015.11.005. Epub 2015 Dec 8. French.

PMID:
26681641
24.

Anticancer treatment and fertility: Effect of therapeutic modalities on reproductive system and functions.

Vassilakopoulou M, Boostandoost E, Papaxoinis G, de La Motte Rouge T, Khayat D, Psyrri A.

Crit Rev Oncol Hematol. 2016 Jan;97:328-34. doi: 10.1016/j.critrevonc.2015.08.002. Epub 2015 Aug 8. Review.

PMID:
26481950
25.

Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.

Goundiam O, Gestraud P, Popova T, De la Motte Rouge T, Fourchotte V, Gentien D, Hupé P, Becette V, Houdayer C, Roman-Roman S, Stern MH, Sastre-Garau X.

Int J Cancer. 2015 Oct 15;137(8):1890-900. doi: 10.1002/ijc.29568. Epub 2015 Apr 29.

26.

[Communication in the context of phase I clinical trials in oncology: implementation and evaluation of training programs].

Rouby P, Hollebecque A, Bahleda R, Deutsch E, Gomez-Rocca C, Angevin E, de La Motte Rouge T, Soria JC, Dauchy S.

Bull Cancer. 2015 Feb;102(2):174-81. doi: 10.1016/j.bulcan.2014.12.013. Epub 2015 Jan 15. French.

PMID:
25609484
27.

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.

Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223. Review.

PMID:
25341580
28.

CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.

Pelissier A, Bonneau C, Chéreau E, de La Motte Rouge T, Fourchotte V, Daraï E, Rouzier R.

Gynecol Oncol. 2014 Dec;135(3):542-6. doi: 10.1016/j.ygyno.2014.09.005. Epub 2014 Sep 16.

PMID:
25223808
29.

[Targeted therapy in locally and metastatic recurrent cervical cancers].

Geiss R, De La Motte Rouge T, Dubot C, Leary A, Lhommé C, Pautier P, Scholl S, Rodrigues MJ.

Bull Cancer. 2014 Jul-Aug;101(7-8):748-55. doi: 10.1684/bdc.2014.1949. Review. French.

PMID:
25091657
30.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
31.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.

Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8.

PMID:
24725337
32.

[Management of enzalutamide, a new hormonal therapy].

Beuzeboc P, Benderra MA, de La Motte Rouge T.

Bull Cancer. 2014 Jan 1;101(1):107-12. doi: 10.1684/bdc.2013.1880. French.

PMID:
24491670
33.

Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours.

Hollande C, Colin P, de La Motte Rouge T, Audenet F, Yates DR, Phé V, Ouzzane A, Droupy S, Ruffion A, de La Taille A, Guy L, Cussenot O, Rozet F, Xylinas E, Zerbib M, Spano JP, Khayat D, Bitker MO, Rouprêt M; French Collaborative National Working-Group on UTUC.

BJU Int. 2014 Apr;113(4):574-80. doi: 10.1111/bju.12308. Epub 2013 Aug 13.

34.

Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.

Rini BI, de La Motte Rouge T, Harzstark AL, Michaelson MD, Liu G, Grünwald V, Ingrosso A, Tortorici MA, Bycott P, Kim S, Bloom J, Motzer RJ.

Clin Genitourin Cancer. 2013 Jun;11(2):107-14. doi: 10.1016/j.clgc.2012.12.004. Epub 2013 Feb 4.

PMID:
23391371
35.

[Non oncologic applications of molecular targeted therapies].

Khaled W, de la Motte Rouge T, Amirault JC, Vignot S.

Bull Cancer. 2012 Oct;99(10):953-62. doi: 10.1684/bdc.2012.1641. Review. French.

36.

Prognostic impact of vitamin B6 metabolism in lung cancer.

Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, Shen S, Tailler M, Niso-Santano M, Morselli E, Criollo A, Adjemian S, Jemaà M, Chaba K, Pailleret C, Michaud M, Pietrocola F, Tajeddine N, de La Motte Rouge T, Araujo N, Morozova N, Robert T, Ripoche H, Commo F, Besse B, Validire P, Fouret P, Robin A, Dorvault N, Girard P, Gouy S, Pautier P, Jägemann N, Nickel AC, Marsili S, Paccard C, Servant N, Hupé P, Behrens C, Behnam-Motlagh P, Kohno K, Cremer I, Damotte D, Alifano M, Midttun O, Ueland PM, Lazar V, Dessen P, Zischka H, Chatelut E, Castedo M, Madeo F, Barillot E, Thomale J, Wistuba II, Sautès-Fridman C, Zitvogel L, Soria JC, Harel-Bellan A, Kroemer G.

Cell Rep. 2012 Aug 30;2(2):257-69. doi: 10.1016/j.celrep.2012.06.017. Epub 2012 Jul 26.

37.

Current role of diethylstilbestrol in the management of advanced prostate cancer.

Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phé V, Bitker MO, Rouprêt M.

BJU Int. 2012 Dec;110(11 Pt C):E826-9. doi: 10.1111/j.1464-410X.2012.11206.x. Epub 2012 May 11. Review.

38.

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Spano JP, Vano Y, Vignot S, De La Motte Rouge T, Hassani L, Mouawad R, Menegaux F, Khayat D, Leenhardt L.

Med Oncol. 2012 Sep;29(3):1421-8. doi: 10.1007/s12032-011-0070-2. Epub 2011 Sep 25.

PMID:
21947747
39.

[Ovarian yolk sac tumour: general review].

Even C, Lhommé C, Duvillard P, Morice P, Balleyguier C, Pautier P, Troalen F, de La Motte Rouge T.

Bull Cancer. 2011 Aug;98(8):963-75. doi: 10.1684/bdc.2011.1387. Review. French.

40.

Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.

Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos MA, Papadimitriou CA, Bamias A, Pignot G, Nouhaud FX, Hurel S, Guy L, Bigot P, Roumiguié M, Rouprêt M; French Collaborative National Database on UUT-UCC.

Cancer. 2011 Dec 15;117(24):5500-8. doi: 10.1002/cncr.26172. Epub 2011 Jun 2.

41.

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T.

Adv Ther. 2011 Apr;28(4):334-40. doi: 10.1007/s12325-011-0007-3. Epub 2011 Mar 14.

PMID:
21432029
42.

Renal cell carcinoma: focus on safety and efficacy of temsirolimus.

Hadoux J, Vignot S, De La Motte Rouge T.

Clin Med Insights Oncol. 2010 Dec 19;4:143-54. doi: 10.4137/CMO.S4482.

43.

[Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].

André T, Wislez M, Goncalves A, de La Motte Rouge T, Blay JY, Massard C, Bay JO; comité de rédaction du Bulletin du Cancer.

Bull Cancer. 2010 Dec;97(12):1551-62. doi: 10.1684/bdc.2010.1221. French.

44.

Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases.

de La Motte Rouge T, Pautier P, Rey A, Duvillard P, Kerbrat P, Troalen F, Morice P, Haie-Meder C, Culine S, Lhommé C.

Eur J Cancer. 2011 Jan;47(2):175-82. doi: 10.1016/j.ejca.2010.08.012. Epub 2010 Sep 28.

PMID:
20851596
45.

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.

Loriot Y, Mordant P, Dorvault N, De la motte Rouge T, Bourhis J, Soria JC, Deutsch E.

Br J Cancer. 2010 Jul 27;103(3):347-53. doi: 10.1038/sj.bjc.6605748. Epub 2010 Jul 13.

46.

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K.

Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. French.

47.

[New drugs and targeted therapeutic agents in ovarian cancer].

de La Motte Rouge T, Petrella MC, Michels J, Even C, Balleyguier C, Duclos J, Mazeron R, Morice P, Pautier P, Lhommé C.

Bull Cancer. 2009 Dec;96(12):1215-24. doi: 10.1684/bdc.2009.0988. Review. French.

48.

Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) Survey.

Loriot Y, Albiges-Sauvin L, Dionysopoulos D, Bouyon-Monteau A, Boyle H, You B, Massard C, de La Motte Rouge T; French Association of Residents in Oncology.

Ann Oncol. 2010 Jan;21(1):161-5. doi: 10.1093/annonc/mdp294. Epub 2009 Jul 23.

PMID:
19628567
49.

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

Serrate C, Loriot Y, De La Motte Rouge T, Gross-Goupil M, Massard C, Escudier B, Bossi A, Fizazi K.

Ann Oncol. 2009 May;20(5):965. doi: 10.1093/annonc/mdp112. No abstract available.

PMID:
19403938
50.

Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.

de La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culine S, Troalen F, Lhommé C.

Ann Oncol. 2008 Aug;19(8):1435-41. doi: 10.1093/annonc/mdn162. Epub 2008 Apr 11.

PMID:
18408223

Supplemental Content

Loading ...
Support Center